Thymalfasin for Immune Recovery in Adults With Sepsis
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 6 Oct 2026
- Expected to end
- 1 Sept 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Thymalfasin (Thymosin alpha 1, Ta1)
- Record updated
- 8 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Age older than 18 years, of any sex. Sepsis according to Sepsis-3 criteria, defined as documented or suspected infection with an increase in Sequential Organ Failure Assessment (SOFA) score of at least 2 points from baseline; APACHE II score of 15 to 30, inclusive, at ICU admission. An immunosuppressed phenotype, defined by reduced monocyte HLA-DR expression meeting No more than 48 hours from sepsis onset to enrollment. Written informed consent provided by the participant or legally authorized representative
Who cannot take part
- Known allergy to thymalfasin or any of its excipients. A history of primary or acquired immunodeficiency, such as HIV infection or post-transplant immunosuppression; Treatment with immunosuppressive agents or immunostimulants within 3 months before enrollment, including systemic corticosteroids at a prednisone-equivalent dose greater than 20 mg/day for at least 7 consecutive days, cyclosporine, tacrolimus, or azathioprine; Active malignancy or ongoing anticancer treatment. Chronic liver disease classified as Child-Pugh class C, or end-stage renal disease requiring maintenance dialysis; Pregnancy or breastfeeding. Expected survival of less than 48 hours at enrollment, such as irreversible brain death after cardiac arrest or terminal multiple organ failure; Concurrent participation in another interventional clinical trial. Any other condition that, in the investigator's judgment, makes participation unsuitable
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a life-threatening illness caused by an abnormal response to infection. Some people with sepsis have reduced immune function, which may make recovery more difficult. This study will examine whether adding thymalfasin, also called thymosin alpha-1, to usual sepsis care improves recovery of immune function.
Read full original descriptionShow less
The study will enroll 60 adults with sepsis and evidence of reduced immune function at Zhongshan Hospital, Fudan University. Participants will be assigned by chance to one of two groups. Thirty participants will receive usual care plus a 1.6 mg thymalfasin injection under the skin twice daily for 7 days. Thirty participants will receive usual care alone, without study-drug or placebo injections.
Participants and treating clinicians will know which treatment is given, but laboratory staff measuring immune outcomes will not know the assigned group. The main outcome is the change in monocyte HLA-DR expression, a blood marker of immune function, between baseline and Day 7. Other assessments include immune cells, organ function, organ support, infections, survival, and safety. Scheduled follow-up continues through Day 90. The study is designed primarily to assess an immune marker; it is not sized to establish a definitive survival benefit.
The 2 groups in the trial
- Thymalfasin Plus Standard CareTreatment being tested
Participants will receive standard sepsis care plus thymalfasin 1.6 mg subcutaneously twice daily, approximately 12 hours apart, for 7 consecutive days (Days 1 to 7). Thirty participants are planned for this arm.
Treatment: Thymalfasin (Thymosin alpha 1, Ta1)
- Standard Care AloneNo study treatment, for comparison
Participants will receive standard sepsis care determined by the treating clinicians, including infection source control, antimicrobial therapy, fluid resuscitation, vasopressors, and organ support as clinically indicated. No thymalfasin or placebo injections will be given as study interventions. Thirty participants are planned for this arm.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Randomized, Controlled Mechanism Study of Thymosin Alpha-1 in Reshaping the "Immune Resilience" Trajectory of Immunosuppressed Sepsis Patients
- Record updated
- 8 October 2026